The purpose of this study is to test whether Amivantamab (JNJ-61186372) and hyaluronidase (rHuPH20) works better at keeping advanced skin cancer from growing or spreading in people who have weakened immune systems than cetuximab. Amivantamab (JNJ-61186372) and hyaluronidase (rHuPH20) or cetuximab could shrink the cancer. The study will randomize (the computer will pick the group that the participant will be enrolled in) participant to Group 1 or Group 2. Participants can expect to be on trial for up to 2 years. After you finish your study treatment, your doctor will continue to follow your condition and watch you for side effects for up to 3 years from the time you joined the study. You'll have follow-up visits with your doctor at least every 3 months. These visits may be done by telephone after you finish treatment. There is evidence that Amivantamab (JNJ-61186372) and hyaluronidase (rHuPH20) is effective in shrinking your type of cancer. Most common side effects are rash, swelling of the arms or legs, skin infection around nails, and tiredness.

This study is for patients that have been newly diagnosed with Acute Myeloid Leukemia and have a NPM1 mutation. This study is testing an investigational drug called Revumenib. "Investigational" means it has not been approved by the United States Food and Drug Administration (FDA). Participants will be randomized, like flipping a coin, into one of two groups. One group will receive revumenib and the other will receive a placebo. The primary purpose of this study is to find out whether the study drug, revumenib, in combination with standard chemotherapy adds any benefit to treating AML when compared to standard chemotherapy alone. Revumenib is given to participants orally. Participants in this study can expect to be in the treatment portion of this study for 2 years. The follow up portion is estimated to last 3 years.

The 12 week study is designed to assess the efficacy and safety of the twice daily ALKS2680, in narcolepsy Type 2. Administered upon wakening and a second time 3-5 hours later, 3 different doses will be compared to a placebo. The effects of ALKS2680 on excessive daytime sleepiness and sleep quality will be examined during overnight and daytime sleep studies.

The 12 week study is designed to assess the efficacy and safety of the twice daily ALKS2680, in narcolepsy Type 1. Administered upon wakening and a second time 5-7 hours later, 2 different doses (6mg and 10mg) will be compared to a placebo. The effects of ALKS2680 on excessive daytime sleepiness and sleep quality will be examined during overnight and daytime sleep studies.

A 95-week study comparing the efficacy and safety of a specific dose of a trial product named zenagamtide versus two different doses of semaglutide, administered once weekly via injection along with a reduced-calorie diet and increased physical activity on weight management in participants with obesity.

This study is for people with advanced head and neck cancer who cannot receive cisplatin. The purpose of this study is to compare treating head and neck cancer with radiation plus cetuximab versus radiation plus chemotherapy (carboplain and paclitaxel). Carboplatin, paclitaxel, and cetuximab are approved by the FDA to treat head and neck cancer.

If you agree to take part, we expect that your participation in this study may last up to 3 years. This includes visits to the clinic after you finish all study treatments. These follow-up visits will take place about every 2 months during the 1st year and about every 4 months thereafter.

Risks may include nausea, vomiting, headache, feeling tired, loss of appetite, and hair loss. Participants may or may not receive a direct benefit from participating in this trial, however, information learned from the trial may help other people in the future.

This study is for patients diagnosed with acute graft-versus-host disease that did not get better with steroids (steroid-refractory) . This study is testing an investigational drug called remestemcel-L-rknd ("remestemcel") with ruxolitinib to placebo with ruxolitinib as treatment for steroid-refractory acute graft-versus-host disease (SR-aGVHD). The study treatment is randomized. This means that a computer assigns you to a treatment group by chance, like flipping a coin or drawing a name out of a hat.The primary purpose of the study is If steroids don't work, patients get a second line of therapy. Doctors and researchers want to find a good treatment for SR-aGVHD as these patients are at a very high risk for medical complications and death. This study will compare patients who receive remestemcel with ruxolitinib and patients who receive placebo with ruxolitinib as a second-line treatment.

This study will look at whether a topical medication called minocycline foam (AMZEEQ) can help treat confluent and reticulated papillomatosis (CARP), a skin condition that causes dark, scaly patches. We will also evaluate how safe the treatment is and how satisfied patients are with it. The study is open to participants ages 9 years and older.

Participants will apply minocycline foam to one side of the affected skin and a moisturizing cream (emollient) to the other side for 5 weeks. This allows us to compare the two treatments in the same person. After this period, participants may choose to continue using the minocycline foam on all affected areas.

During the study, participants will attend follow-up visits where photos of the skin will be taken and the condition of the skin will be evaluated. Participants will also complete brief surveys about how their skin condition affects their quality of life and how satisfied they are with the treatment. The research team will monitor treatment use and any side effects.

The goal of this study is to learn whether topical minocycline could be a safe and effective treatment option for CARP, potentially providing an alternative to oral antibiotics.

This study is for newly diagnosed participants with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia. This study is testing an oral drug called Asciminib in a new patient population. While Asciminib is approved by the United States Food and Drug Administration (FDA) for Chronic Myeloid Leukemia, it has not been approved in Acute Lymphoblastic Leukemia participants. Therefore, it's use in Acute Lymphoblastic Leukemia participants is investigational. The purpose of this study is to test if adding the investigational study drug asciminib to usual treatment will improve how chemotherapy works against Ph+ ALL. Participants can expect to be in this study as long as it helps them.

This study is recruiting pediatric patients who have been diagnosed with Favorable Histology Wilms Tumor (FHWT). Wilms Tumor is the most common type of kidney cancer in children, and FHWT is the most common subtype. The goal of the study to improve outcomes within cohorts of FHWT patients with current long-term EFS rates at or below 80% and maintain outcomes despite therapy reduction within cohorts of FHWT patients with current long-term EFS rates at or above 84%. Common side effects of treatment in regards to this study include nausea, vomiting, hair loss, and fatigue (tiredness). Participants will receive the medications through an IV in their arm and orally. Study participation is expected to be approximately 5 years.